ObjectiveaaIt is important to predict a response to an antidepressant in early time after starting the antidepressant. We previously reported that serum brain-derived neurotrophic factor (BDNF) levels in responders to treatment with antidepressants were increased, whereas, those in nonresponders were not. Therefore, we hypothesized that the changes in serum levels of BDNF from baseline (T0) to 4 weeks (T4) after treatment with selective serotonin reuptake inhibitors (SSRIs) predict the response to the treatment at 8 weeks (T8) in depressed patients. To confirm the hypothesis, we measured serum BDNF at T0, T4, and T8 during the treatment with SSRIs (paroxetine, sertraline, and fluvoxamine). MethodsaaOne hundred fifty patients (M/F; 51/99, age; 50.4±15.1 years) met major depressive disorder (MDD) using by DSM-IV-TR enrolled in the present study. We measured serum BDNF concentrations at T0, T4, and T8 in patients with MDD treated with SSRIs. ResultsaaThe changes in serum BDNF, age, sex, dose of SSRIs, and HAMD-17 score did not predict the response to SSRIs at T8. ConclusionaaThese results suggest that the changes in serum BDNF levels from T0 to T4 could not predict the subsequent responses to SSRIs at T8.
INTRODUCTION
Treatment of depression with currently available antidepressants is not satisfied, because only 30-40% of real-life patients with major depressive disorder reach a remission with the first selected antidepressant. 1 Therefore, it is important to develop new strategies to increase remission rates and to shorten the time to remission. Prediction of response to antidepressants at early period after starting the antidepressant is necessary to decide continuing the antidepressant, changing other one, or augmentation strategy. A substantial body of evidence from many retrospective studies shows that non-improvement, often defined as <20% reduction of depressive symp-
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toms assessed with a routine scale like the Hamilton Rating Scale for Depression (HAMD) 2 after 14 days of treatment is a highly specific marker for final treatment failure with an unchanged treatment. 3 Brain-derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of depression. 4, 5 In addition, blood (serum or plasma) levels of BDNF is a biomarker for depressive state. [6] [7] [8] [9] We previously reported that baseline serum BDNF levels predict subsequent response to mirtazapine in Japanese patients with major depressive disorder. 10 In another study, we demonstrated that baseline serum BDNF levels did not significantly different between responder and non-responders to selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor medications. 11, 12 Wolkowitz et al. 13 reported that pre-treatment serum BDNF levels were significantly higher in the responders than in the non-responders. From these findings into account, it is controversial baseline serum BDNF levels could predict later response to treatment with antidepressants. Recently, Tadic et al. 14 reported that the non-increase of serum BDNF level and the non-improvement of HAMD from baseline to day 7 or 14
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Reiji Yoshimura predicted later non-response and non-remission with moderate to high specificity. In clinical practice, prediction for response to antidepressants within an early point is an important issue. Therefore, we hypothesized that serum levels 4 weeks after starting SSRIs could predict subsequent response to SSRIs, it could help to decide in changing other antidepressants, increase the same antidepressant, or choosing augmentation strategy.
We consider that if changes in serum BDNF levels at early point predict the subsequent outcome of the response to SSRIs, the changes in serum BDNF levels might become useful tool for predictions for SSRIs response. To confirm the hypothesis, we examined the relation between serum BDNF levels at 4 weeks and subsequent clinical response to SSRIs.
METHODS
This study included 150 in-or outpatients in our university hospital who met the DSM-IV-TR criteria 15 for major depressive disorder without psychotic features and who scored at least 16 on the 17-items of the Hamilton Raring Scale for Depression (HAMD-17). Fifty-one patients were male and 99 were female. The age of the subjects ranged from 22 to 76 years (mean±SD=50.4±15.1). None had received any antidepressant drugs or mood stabilizers at least two weeks prior to the study. All patients were physically healthy and no subjects had a history of alcohol and/or drug abuse. None had co-morbid any anxiety disorders and personality disorders. The patients were treated with paroxetine, sertraline, or fluvoxamine. There were 60 cases treated with paroxetine, 72 cases treated with sertraline, and 28 cases treated with fluvoxamine. Initial dose of paroxetine, sertraline, or fluvoxamine were 10 mg/day, 25 mg/day, or 25 mg/day, respectively, and the dose was increased until the patients tolerated adverse effects (the dose was not fixed). Maximum dose of paroxetine, sertraline or fluvoxamine were 40 mg/day, 100 mg/day, or 150 mg/day, respectively. The average dose of each antidepressant was as follows; paroxetine: 30.5±12.4 mg/day, sertraline: 76.7±24.0 mg/ day, fluvoxamine: 100±26.3 mg/day. We evaluated the severity of depressive state using the HAMD-17 before (T0) and 4 (T4) and 8 weeks (T8) after treatment with paroxetine, sertraline, or fluvoxamine. We defined the patients whose scores of the HAMD-17 decreased 50% or more as responders, whereas, below 50% as nonresponders.
All blood samples were taken at 7:00 am before breakfast (at least 12 hours after the last medication) before (T0) and 4 (T4) and 8 weeks (T8) after treatment with paroxetine, sertraline, or fluvoxamine. Fifteen milliliters of venous blood was drawn with the patient in the supine position, after the patient had been lying at rest overnight. The serum samples were quickly separated in a centrifuge (2000 g, 10 min, 4°C) and stored at -80°C until assay. The serum BDNF levels were measured using a BDNF Emax Immunoassay Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. In short, 96-well microplates were coated with anti-BDNF monoclonal antibody and incubated at 4°C for 18 hours. The plates were incubated in a blocking buffer for 1 hour at room temperature. The samples diluted with assay buffer by 100-times and BDNF standards were kept at room temperature under conditions of horizontal shaking for 2 hours, followed by washing with the appropriate washing buffer. The plates were incubated with antihuman BDNF polyclonal antibody at room temperature for 2 hours and washed with the washing buffer. The plates were then incubated with anti-IgY antibody conjugated to horseradish peroxidase for 1 hour at room temperature, and incubated in peroxidase substrate and tetramethylbenzidine solution to induce a color reaction. The reaction was stopped with 1 mol/L hydrochloric acid. The absorbance at 450 nm was measured with an Emax automated microplate reader. Measurements were performed in duplicates. The standard curve was linear from 5 pg/mL to 5000 pg/mL, and the detection limit was 10 pg/mL. Cross-reactivity to related neurotrophins (NT-3, NT-4, NGF) was less than 3%. Intra-and interassay coefficients of variation were about 5% and 7%, respectively. The recovery rate of the exogenous added BDNF in the measured plasma samples was more than 95%.
Actually, we examined the change of serum BDNF levels in same samples in a same day at time 8:00, 12:00, 16:00, 20:00, 24:00, and no significant changes in serum BDNF were observed within a day (data not shown). This study was approved by the ethics committee of the University of Occupational and Environmental Health, and written informed consent was obtained from all participants.
Statistical analysis
The logistic regression analysis was performed for the response to SSRIs at T4 as a dependent variable and changes in BDNF, sex, age, dose of SSRIs at T8, and HAMD-17 at T0 as independent variables. The area under the curve (ROC-AUC) was made for the prediction of the response at T8 with using a BDNF change from T0 to T4. We used the repeated measures of ANOVA comparing HAMD-17 scores and serum BDNF levels at each point. Significance was set at <0.05. All analyses were done using the Japanese version of SPSS v15.1 (SPSS, Tokyo, Japan).
RESULTS
Among 150 patients, 70 (46.3%) were responders to treat of SSRIs at week 8, and the rest (53.3%) were nonresponders.
Any independent variables (changes in BDNF, sex, age, dose of SSRIs, and HAMD-17 at T0) were not associated with the response at T8 ( Table 1) . The AUC of a BDNF change from T0 to T4 was 0.54 for the response to at T8 (p=0.311, 95% confidence interval=0.137-0.681) (Figure 1 ). Significantly positive correlations were not observed between the changes in HA-MD-17 (T0-8) or (T0-4) and the changes in BDNF (T8-T0) or (T4-T0) (r=0.005, p=0.524) (r=0.170, p=0.9107) (Figures 2  and 3 ). The scores of HAMD-17 significantly decreased from at T0 (21.0±4.3) to at T4 (13.8±4.9) and at T8 (10.0±5.6) (p< 0.0001) (Figure 4) . The serum BDNF levels significantly increased from at T0 (8.6±7.2 ng/mL) to at T8 (11.2±8.4 ng/mL), but not at T4 (9.2±6.1 ng/mL) (p=0.018) ( Figure 5 ). 
DISCUSSION
Treatment with SSRIs for 4 or 8 weeks significantly decreased the HAMD-17 scores in patients with MDD, and also increased serum BDNF levels at T8, but not at T4 (Figures 4 and 5) .
In the present study, we demonstrated that changes in serum BDNF, sex, age, dose of SSRIs, and HAMD17 at baseline were not associated with the clinical response to SSRIs at day 28. The results in the present study revealed that the changes in serum BDNF and the HAMD-17 were both independent of the clinical outcome. Tadic et al. 14 reported that the individual marker early serum BDNF non-increase has a positive predictive value for final treatment failure. In addition, Dreimuller et al. 16 reported the changes in plasma BDNF at day 7 combined with HAMD improvement might be a predictor for good response to antidepressants. The between in the present study and those recent studies remain unknown. The early changes in BDNF only could not predict subsequently response to SSRIs. In other word, it might be necessary to combine the changes in HAMD scores. To the best of our knowledge, there have been at least four meta-analyses of studies of blood BDNF levels in depressed patients. [6] [7] [8] [9] The results of previous investigations have generally revealed that blood BDNF levels in depressed patients are significantly lower than those of healthy subjects. Taken together, these findings suggest that blood BDNF levels are a candidate biomarker for depression. However, it seems difficult to predict subsequent responses to SSRIs at early point of serum BDNF levels only. Actually, we previously reported that serum BDNF levels were not changed at all at T4, and were for the first time increased at T8. The results in the present study were not contradicted to our previous results in our previous study. 11 In short, it takes at least 8 weeks or more to change the serum BDNF levels in patients with response to SSRIs. Furthermore, the AUC value in the present study was 0.54, and the ROC was almost linear suggesting the prediction for response to SSRIs using the changes in serum BDNF levels (T0-T4)/T0 is low and not useful (Figure 1 ). This result was not contradicted with the results that no correlations were found the changes in HAMD (T0-4) or (T0-8) and the changes in BDNF (T4-0) or BDNF (T8-0).
There are several limitations in the present study. The source of circulating BDNF remains unknown. Platelets, brain, and vascular endothelial cells are considered candidate sources. BDNF assessed in serum represented the portion of BDNF stored in platelets, which bind, store, and release BDNF upon activation by a number factors, including physiological stress and injuries. But, even with agonist stimulation only about half of the BDNF in platelets is secreted, which suggests that platelets maintain a stable pool of BDNF, a buffer system. 17 Previously, it was reported that BDNF levels in the brain and serum underwent similar changes during maturation and aging process in rats, 18 indicating that plasma BDNF levels might in part reflect the BDNF in the brain. In contrast to this, Radka et al. 19 reported that the BDNF detected in human serum was derived from platelet degranulation, and that circulating levels of BDNF are negligible. Furthermore, the plasma assay measures BDNF released in the blood, which is quite unstable. Plasma BDNF, for example, has very low retest stability when measured twice within one year, and there are substantial changes even during one day. Such variation is one drawback to assessing BDNF in plasma and may help explain the lack of association with measures of depression. Previous studies have also reported that a large degree of dispersion, which suggests that it is a problematic feature of the plasma BDNF measurement. A recent study also raises methodological concerns regarding the assessment of BDNF in plasma and recommends measuring BDNF in serum. 17 From these findings into account, it is not clear as to what extent peripheral BDNF reflects central BDNF. Since it is well established that platelets are the major source of peripheral BDNF, 17, 21 it would be nice to have the BDNF data presented also in the framework of platelet counts of the investigated subjects. Furthermore, there is increasing evidence that sampling characteristics, several sociodemographic variables (such as urbanicity, age, sex), lifestyle factors (such as smoking status and food and alcohol intake), somatic diseases and even self-reported depressive symptoms are relevant determinants of peripheral BDNF levels. [17] [18] [19] Thus, it is mandatory that the results presented are discussed with respect to these determinants. Therefore, further precise and well-controlled study considering above problems should be done to lead to robust results.
In conclusion, the changes in only serum BDNF levels from T0 to T4 could not predict the subsequent responses to SSRIs at T8. 
